CTIC Share Price

Open 3.10 Change Price %
High 3.14 1 Day -0.07 -2.24
Low 3.04 1 Week 0.00 0.00
Close 3.05 1 Month -0.26 -7.85
Volume 63972 1 Year 2.65 662.50
52 Week High 6.48
52 Week Low 0.38
CTIC Important Levels
Resistance 2 3.14
Resistance 1 3.10
Pivot 3.08
Support 1 3.00
Support 2 2.96
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Cell Therapeutics, Inc. (NASDAQ: CTIC)

CTIC Technical Analysis 4
As on 31st Oct 2017 CTIC Share Price closed @ 3.05 and we RECOMMEND Sell for LONG-TERM with Stoploss of 3.53 & Strong Sell for SHORT-TERM with Stoploss of 3.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
CTIC Target for November
1st Target up-side 3.27
2nd Target up-side 3.43
3rd Target up-side 3.59
1st Target down-side 2.83
2nd Target down-side 2.67
3rd Target down-side 2.51
CTIC Other Details
Segment EQ
Market Capital 134819600.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celltherapeutics.com
CTIC Address
CTIC
3101 Western Avenue
Suite 600
Seattle, WA 98121
United States
Phone: 206-282-7100
Fax: 206-284-6206
CTIC Latest News
Interactive Technical Analysis Chart Cell Therapeutics, Inc. ( CTIC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cell Therapeutics, Inc.
CTIC Business Profile
Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company is concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. The Company is primarily focused on commercializing PIXUVRI (pixantrone) in the European Union for multiplies relapsed or refractory aggressive non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial of pacritinib for the treatment of myelofibrosis. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects.